Median highlights AI lung cancer research

2016 12 21 15 11 05 414 Lung Cancer 400

Median Technologies has released trial results showing that its artificial intelligence (AI) algorithm performed well in characterizing malignant and benign lung nodules in patients receiving low-dose chest CT lung cancer screening.

The company's new iBiopsy computer-aided diagnosis (CADx) algorithm was trained on a dataset from 1,224 patients with 11,392 nodules from the National Lung Screening Trial and then tested on CT images from 472 patients with 4,216 nodules. The application yielded 95.2% sensitivity and 95.7% specificity for lung nodule characterization, as well as an area under the curve of 0.991, Median said.

The company is planning an additional large-scale study for an end-to-end digital lung cancer screening application that will provide both nodule detection and characterization. Results are expected in the fourth quarter.

Page 1 of 110
Next Page